loading
前日終値:
$654.04
開ける:
$649.45
24時間の取引高:
240.49K
Relative Volume:
0.23
時価総額:
$68.04B
収益:
$14.25B
当期純損益:
$4.58B
株価収益率:
15.64
EPS:
41.7701
ネットキャッシュフロー:
$3.88B
1週間 パフォーマンス:
+13.16%
1か月 パフォーマンス:
+16.31%
6か月 パフォーマンス:
+9.22%
1年 パフォーマンス:
-21.98%
1日の値動き範囲:
Value
$645.00
$660.00
1週間の範囲:
Value
$575.93
$664.00
52週間の値動き範囲:
Value
$476.49
$862.00

Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile

Name
名前
Regeneron Pharmaceuticals Inc
Name
セクター
Healthcare (1144)
Name
電話
(914) 847-7000
Name
住所
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Name
職員
15,207
Name
Twitter
@regeneron
Name
次回の収益日
2025-08-01
Name
最新のSEC提出書
Name
REGN's Discussions on Twitter

REGN を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
653.12 68.74B 14.25B 4.58B 3.88B 41.77
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
422.44 107.66B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
451.84 58.93B 2.46B -319.09M -52.09M -2.4669
Biotechnology icon
ARGX
Argen X Se Adr
813.89 50.51B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
INSM
Insmed Inc
190.15 41.29B 398.11M -1.03B -868.57M -5.7032

Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-08-14 開始されました Rothschild & Co Redburn Buy
2025-06-30 ダウングレード Argus Buy → Hold
2025-05-30 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2025-05-30 ダウングレード Wells Fargo Overweight → Equal Weight
2025-05-14 アップグレード Citigroup Neutral → Buy
2025-04-22 再開されました Cantor Fitzgerald Overweight
2025-02-05 アップグレード Leerink Partners Market Perform → Outperform
2025-01-16 ダウングレード UBS Buy → Neutral
2024-12-10 再開されました BofA Securities Underperform
2024-11-15 開始されました Wolfe Research Outperform
2024-11-14 開始されました Citigroup Neutral
2024-09-24 ダウングレード Leerink Partners Outperform → Market Perform
2024-03-12 開始されました Bernstein Outperform
2024-01-12 アップグレード RBC Capital Mkts Sector Perform → Outperform
2023-11-09 開始されました Deutsche Bank Hold
2023-11-03 アップグレード Raymond James Mkt Perform → Outperform
2023-08-21 アップグレード Canaccord Genuity Hold → Buy
2023-08-21 繰り返されました Oppenheimer Perform
2023-06-28 ダウングレード Canaccord Genuity Buy → Hold
2023-03-27 アップグレード SVB Securities Market Perform → Outperform
2023-03-24 アップグレード Jefferies Hold → Buy
2023-03-23 アップグレード Raymond James Underperform → Mkt Perform
2023-01-30 アップグレード Cowen Market Perform → Outperform
2023-01-20 アップグレード JP Morgan Neutral → Overweight
2022-10-26 ダウングレード Raymond James Mkt Perform → Underperform
2022-10-17 ダウングレード Evercore ISI Outperform → In-line
2022-09-09 アップグレード Jefferies Underperform → Hold
2022-09-09 アップグレード Morgan Stanley Equal-Weight → Overweight
2022-07-25 ダウングレード SVB Leerink Outperform → Mkt Perform
2022-07-13 開始されました Cantor Fitzgerald Neutral
2022-06-06 開始されました Jefferies Underperform
2022-05-23 開始されました SVB Leerink Outperform
2022-01-05 ダウングレード BofA Securities Neutral → Underperform
2022-01-03 アップグレード Bernstein Mkt Perform → Outperform
2021-12-15 ダウングレード Bernstein Outperform → Mkt Perform
2021-12-09 再開されました Wells Fargo Overweight
2021-12-07 再開されました Cowen Market Perform
2021-12-06 開始されました Goldman Buy
2021-11-19 再開されました BMO Capital Markets Outperform
2021-11-05 ダウングレード The Benchmark Company Buy → Hold
2021-06-29 開始されました H.C. Wainwright Buy
2021-01-25 アップグレード BMO Capital Markets Market Perform → Outperform
2021-01-13 アップグレード The Benchmark Company Hold → Buy
2021-01-08 アップグレード Citigroup Neutral → Buy
2020-10-05 アップグレード Cantor Fitzgerald Neutral → Overweight
2020-08-20 ダウングレード The Benchmark Company Buy → Hold
2020-07-09 アップグレード SunTrust Hold → Buy
2020-05-26 アップグレード Wells Fargo Equal Weight → Overweight
2020-04-28 ダウングレード Citigroup Buy → Neutral
2020-04-17 アップグレード The Benchmark Company Hold → Buy
2020-04-08 開始されました The Benchmark Company Hold
2020-03-31 開始されました Wolfe Research Peer Perform
2020-02-27 開始されました Barclays Overweight
2020-02-26 アップグレード Canaccord Genuity Hold → Buy
2020-02-26 ダウングレード Robert W. Baird Outperform → Neutral
2020-02-25 アップグレード Jefferies Hold → Buy
2020-02-11 アップグレード Argus Hold → Buy
2019-12-24 開始されました Raymond James Mkt Perform
2019-12-16 ダウングレード Evercore ISI Outperform → In-line
2019-12-13 アップグレード Credit Suisse Neutral → Outperform
2019-11-12 開始されました SunTrust Hold
2019-11-07 アップグレード Citigroup Neutral → Buy
2019-10-17 再開されました BofA/Merrill Neutral
2019-09-23 アップグレード Guggenheim Neutral → Buy
すべてを表示

Regeneron Pharmaceuticals Inc (REGN) 最新ニュース

pulisher
08:48 AM

Dupixent wins 2025 Prix Galien USA Best Biotechnology Product award - PharmaLive

08:48 AM
pulisher
08:31 AM

UNIVEST FINANCIAL Corp Boosts Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

08:31 AM
pulisher
07:30 AM

Libtayo® (cemiplimab for injection) Now Reimbursed in Québec for Advanced Non-Small Cell Lung Cancer - BioSpace

07:30 AM
pulisher
07:30 AM

Libtayo® (cemiplimab for injection) Now Reimbursed in Seven Provinces for Advanced Non-Small Cell Lung Cancer and Locally Advanced Basal Cell Carcinoma - BioSpace

07:30 AM
pulisher
07:12 AM

Retirement Systems of Alabama Has $67.81 Million Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

07:12 AM
pulisher
07:11 AM

Regeneron Pharmaceuticals' Dupixent® Awarded "Best Biotechnology Product" by Galien Foundation for 2025 - Quiver Quantitative

07:11 AM
pulisher
07:00 AM

Dupixent® (dupilumab) Wins Prestigious 2025 Prix Galien USA Best Biotechnology Product Award - Caledonian Record

07:00 AM
pulisher
07:00 AM

Dupixent® (dupilumab) Wins Prestigious 2025 Prix Galien USA Best Biotechnology Product Award - GlobeNewswire Inc.

07:00 AM
pulisher
06:27 AM

Why Regeneron Pharmaceuticals Inc. (RGO) stock is a strong buy callCPI Data & Reliable Breakout Forecasts - newser.com

06:27 AM
pulisher
06:19 AM

News impact scoring models applied to Regeneron Pharmaceuticals Inc.Market Growth Summary & Consistent Profit Focused Trading Strategies - newser.com

06:19 AM
pulisher
06:12 AM

Heatmap analysis for Regeneron Pharmaceuticals Inc. and competitorsWeekly Loss Report & Free Long-Term Investment Growth Plans - newser.com

06:12 AM
pulisher
06:00 AM

JW Therapeutics and Regeneron Expand Strategic Collaboration Agreement to Advance TCR-T Cell Therapy Development and Maximize Global Platform Potential - The Manila Times

06:00 AM
pulisher
05:17 AM

Using fundamentals and technicals on Regeneron Pharmaceuticals Inc.Long Setup & Technical Entry and Exit Alerts - newser.com

05:17 AM
pulisher
04:46 AM

Why Regeneron Pharmaceuticals Inc. (RGO) stock is listed among top recommendationsTrade Volume Summary & Low Volatility Stock Suggestions - newser.com

04:46 AM
pulisher
12:42 PM

How currency fluctuations impact Regeneron Pharmaceuticals Inc. stockPortfolio Update Report & Breakout Confirmation Trade Signals - newser.com

12:42 PM
pulisher
12:42 PM

Why Regeneron Pharmaceuticals Inc. stock is considered a top pickEarnings Trend Report & Real-Time Buy Signal Alerts - newser.com

12:42 PM
pulisher
Oct 30, 2025

Opko Health Inc.’s (OPK) ModeX Therapeutics Announces License and Collaboration Agreement With Regeneron Pharmaceuticals - Insider Monkey

Oct 30, 2025
pulisher
Oct 30, 2025

Biopharma stocks regain ground in Q3 but still lag major indexes - BioWorld MedTech

Oct 30, 2025
pulisher
Oct 30, 2025

Citigroup Issues Positive Forecast for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price - MarketBeat

Oct 30, 2025
pulisher
Oct 30, 2025

Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $708.00 at Royal Bank Of Canada - MarketBeat

Oct 30, 2025
pulisher
Oct 30, 2025

Regeneron receives FDA CRL, delaying Eylea HD sBLA approval - Eyes On Eyecare

Oct 30, 2025
pulisher
Oct 30, 2025

Wells Fargo & Company Issues Positive Forecast for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price - MarketBeat

Oct 30, 2025
pulisher
Oct 30, 2025

Cantor Fitzgerald Boosts Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $740.00 - MarketBeat

Oct 30, 2025
pulisher
Oct 30, 2025

Regeneron (REGN) Margin Compression Reinforces Cautious Community Narratives Heading Into Earnings Season - Yahoo Finance

Oct 30, 2025
pulisher
Oct 30, 2025

Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $865.00 at Guggenheim - MarketBeat

Oct 30, 2025
pulisher
Oct 30, 2025

In a $1B+ deal, Modex joins with Regeneron to develop antibodies - BioWorld MedTech

Oct 30, 2025
pulisher
Oct 30, 2025

Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price Expected to Rise, Bank of America Analyst Says - MarketBeat

Oct 30, 2025
pulisher
Oct 30, 2025

Can Regeneron Pharmaceuticals Inc. stock maintain operating marginsTrade Exit Report & Verified Swing Trading Watchlists - newser.com

Oct 30, 2025
pulisher
Oct 30, 2025

Regeneron (REGN) Margin Dip Underscores Market Caution Despite Strong Relative Valuation - simplywall.st

Oct 30, 2025
pulisher
Oct 30, 2025

Regeneron Pharmaceuticals, Inc. $REGN Shares Purchased by Evergreen Wealth Management LLC - MarketBeat

Oct 30, 2025
pulisher
Oct 30, 2025

Wealthfront Advisers LLC Sells 1,560 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Oct 30, 2025
pulisher
Oct 30, 2025

Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by AlphaQuest LLC - MarketBeat

Oct 30, 2025
pulisher
Oct 30, 2025

Why millennials buy Regeneron Pharmaceuticals Inc. (RGO) stockJuly 2025 PostEarnings & AI Driven Stock Price Forecasts - newser.com

Oct 30, 2025
pulisher
Oct 30, 2025

What MACD signals say about Regeneron Pharmaceuticals Inc.July 2025 Rallies & Low Drawdown Momentum Ideas - newser.com

Oct 30, 2025
pulisher
Oct 30, 2025

Combining price and volume data for Regeneron Pharmaceuticals Inc.Market Performance Report & Long-Term Capital Growth Strategies - newser.com

Oct 30, 2025
pulisher
Oct 29, 2025

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to Issue $0.88 Quarterly Dividend - MarketBeat

Oct 29, 2025
pulisher
Oct 29, 2025

Regeneron receives another CRL for its Eylea 8 mg - Ophthalmology Times

Oct 29, 2025
pulisher
Oct 29, 2025

Regeneron's Portfolio Still Supports a Narrow Moat Despite Competitive Threats to Eylea - Morningstar

Oct 29, 2025
pulisher
Oct 29, 2025

REGN Receives Analyst Rating Boost with New Price Target | REGN Stock News - GuruFocus

Oct 29, 2025
pulisher
Oct 29, 2025

Regeneron Pharmaceuticals (REGN) Sees Revised Price Target by RB - GuruFocus

Oct 29, 2025
pulisher
Oct 29, 2025

Regeneron Q3 Earnings Review: This Is The Start Of A Dupixent Driven Comeback (REGN) - Seeking Alpha

Oct 29, 2025
pulisher
Oct 29, 2025

Regeneron’s Aflibercept Study Sheds Light on Retinal Vasculitis Incidence - TipRanks

Oct 29, 2025
pulisher
Oct 29, 2025

Regeneron Adds Fuel to Hot Healthcare Trade. Which Stocks Could Follow it Higher? - Barron's

Oct 29, 2025
pulisher
Oct 29, 2025

Market Starting To Embrace The 'New' Regeneron (NASDAQ:REGN) - Seeking Alpha

Oct 29, 2025
pulisher
Oct 29, 2025

Regeneron pledges more than $1B biobucks for ModeX multispecific antibodies - Fierce Biotech

Oct 29, 2025
pulisher
Oct 29, 2025

Regeneron Pharmaceuticals (NASDAQ:REGN) Shares Gap Up Following Earnings Beat - MarketBeat

Oct 29, 2025
pulisher
Oct 29, 2025

Wells Fargo Raises Regeneron (REGN) Price Target Amidst Equal-We - GuruFocus

Oct 29, 2025
pulisher
Oct 29, 2025

Regeneron teams up with Gary Nabel’s ModeX on multispecifics - Endpoints News

Oct 29, 2025
pulisher
Oct 29, 2025

Cantor Fitzgerald Boosts Price Target for Regeneron Pharmaceuticals (REGN) | REGN Stock News - GuruFocus

Oct 29, 2025
pulisher
Oct 29, 2025

Regeneron Pharmaceuticals (NASDAQ:REGN) Announces Earnings Results, Beats Estimates By $2.10 EPS - MarketBeat

Oct 29, 2025
pulisher
Oct 29, 2025

Guggenheim Raises Regeneron Pharmaceuticals (REGN) Price Target to $865 | REGN Stock News - GuruFocus

Oct 29, 2025

Regeneron Pharmaceuticals Inc (REGN) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Regeneron Pharmaceuticals Inc (REGN) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
SING GEORGE L
Director
Dec 31 '24
Option Exercise
413.33
3,338
1,379,696
29,610
McCourt Marion
EVP Commercial
Nov 01 '24
Option Exercise
381.40
1,000
381,400
13,931
McCourt Marion
EVP Commercial
Nov 01 '24
Sale
844.61
1,000
844,610
12,931
$451.84
price up icon 0.37%
$812.85
price down icon 0.67%
$191.06
price down icon 1.61%
biotechnology ONC
$309.13
price up icon 0.62%
$422.37
price up icon 0.60%
大文字化:     |  ボリューム (24 時間):